Stockreport

Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer’s Risk Profiling

Quanterix Corporation  (QTRX) 
US:NASDAQ Investor Relations: ir.quanterix.com/investor-relations
PDF Analysis of Subjective Cognitive Decline (SCD) cohort indicates that combining biomarkers representing four key biological axes—amyloid, tau, neurodegeneration, and neur [Read more]